Bristol widens drug-licensing partnership with Ono

09/21/2011 | Reuters

Bristol-Myers Squibb gained rights to investigational cancer immunotherapy BMS-936558/ONO-4538 in all countries except Taiwan, Japan and South Korea through an expanded agreement with Ono Pharmaceutical. Bristol already had exclusivity in North America. In exchange, Ono gets co-development and -marketing rights in Japan to Orencia, Bristol's rheumatoid arthritis drug.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT